During TIDES: Oligonucleotide & Peptide Therapeutics, San Diego, USA, meet our experts to learn more about our oligonucleotide analytical development services. Booth 202, 20 -23 May 2019
During TIDES: Oligonucleotide & Peptide Therapeutics 2019, Intertek will present on analytical development strategies which help to accelerate oligonucleotide product development from early characterisation to late-stage development & commercialization. Meet our team in San Diego, USA. Contact us to arrange a meeting during the event.
Approaches to Data Analysis for CMC Testing of Oligonucleotide Therapeutics
Thursday, May 23, 2019, 12:20pm, Main Conference
Dr Jo-Anne Riley, Senior Scientist, Oligonucleotide Services
As oligonucleotide drug candidates progresses through the discovery and development phases and into clinical trials and beyond, the analytical testing strategies must also evolve. Defining each aspect of an analytical method, including data acquisition, data processing, calculations and reporting, requires consideration of the variety of approaches available. This presentation will include a discussion of accurate mass analysis and impurity testing.
If you would like a copy of the presentation, please send a request now to receive the slides after the event.
Meet Our Expert:
Jo-Anne began her analytical chemistry career in 2007 with an undergraduate placement in the Structural and Separation Science team at Pfizer. This was followed by a Chemistry PhD at the University of Southampton focussed on mass spectrometry of oligonucleotides. Jo-Anne has five years’ experience working to cGMP standards performing analytical method development and validation and routine analysis for batch release and stability studies using a range of analytical techniques. This academic background in therapeutic oligonucleotides combined with industrial experience of GMP analysis led to Jo-Anne joining Intertek’s Oligonucleotide Services team in April 2018.
Case Study: Identification Testing by Accurate Mass and MS/MS Sequencing
Case Study: Oligonucleotide Identification, Assay and Impurities
Case Study: Determination of Melting Temperature for Oligonucleotide Duplexes using NMR
Article Download: Analytical challenges in the oligonucleotide characterisation
White Paper: Analytical Strategies for Quality Control of Oligonucleotide Therapeutics
With a growing global development pipeline of oligonucleotide therapeutics to treat a variety of disease targets, overcoming the challenges of innovation, regulatory authorization, production and the inherent complexity of oligos is critical to success. Contact our experts in oligonucleotide analysis and bioanalysis, to discuss our regulatory-driven, phase-appropriate characterization and biophysical analysis in support of CMC programs which GMP and CMC laboratory services, pharmaceutical analysis, quality control analysis, elemental impurities, extractables and leachables, stability programs, inhalation drug development, method development and method validation will be available to review your challenges and discuss and how our unrivalled expertise can help you to accelerate the development timelines.
Need help or have a question?